| Description |
Sematilide (CK-1752) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent[1].
|
| Related Catalog |
|
| Target |
IC50: 25 μM (K+ current)[1]
|
| In Vitro |
Application of 10, 30, 100 and 300 μM Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM)[1].
|
| In Vivo |
Sematilide (0.3-1.0 mg/kg, intravenously i.v.) is effective in a canine model of arrhythmia[2]. Animal Model: Mongrel dogs of either sex (10-18 kg body weight)[2] Dosage: 0.3, 1, 3, and 10 mg/kg Administration: I.v. infusions Result: Demonstrated antiarrhythmic effects at 0.3 and 3.0 mg/kg.
|
| References |
[1]. Ishii Y, et al. Effects of Sematilide, a novel class III antiarrhythmic agent, on membrane currents in rabbit atrial myocytes. Eur J Pharmacol. 1997 Jul 23;331(2-3):295-302. [2]. Stanley S. Greenberg, et al. Pharmacology of Sematilide, a non-quaternary class III antiarrhythmic agent.
|
